MS-PEMEDIUM SIGNALFINANCIAL10-Q

Morgan Stanley reported meaningfully improved quarterly performance with higher ROE, better expense efficiency, and stronger revenue generation across both Institutional Securities and Wealth Management divisions.

The firm's ROE expansion from 13.9% to 18.0% and efficiency ratio improvement from 71% to 67% demonstrates effective operational execution and cost discipline. The revenue increases in both major business segments - Institutional Securities growing to $8.5 billion from $7.6 billion and Wealth Management reaching $8.2 billion from $7.8 billion - suggest broad-based business momentum and successful client engagement across markets.

Comparing 2025-11-03 vs 2025-08-04View on EDGAR →
FINANCIAL ANALYSIS

Morgan Stanley's financial position strengthened notably with net income growing 20.8% to $5.6 billion and operating cash flow improving substantially from negative $24.0 billion to negative $7.1 billion. The firm expanded its balance sheet with total assets reaching $1.6 trillion (up 11.3%) and cash equivalents increasing 19.5% to $133.5 billion, while also returning more capital to shareholders through increased buybacks of $306 million. The overall picture signals improved profitability, enhanced liquidity positioning, and continued capital allocation discipline.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+70.4%
-$24.0B-$7.1B

Operating cash flow surged 70.4% — exceptional cash generation, highest quality earnings signal.

Share Buybacks
Cash Flow
+67.2%
$183.0M$306.0M

Share repurchases increased 67.2% — management returning capital, signals confidence in intrinsic value.

Net Income
P&L
+20.8%
$4.6B$5.6B

Net income grew 20.8% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
+19.5%
$111.7B$133.5B

Cash grew 19.5% — improving liquidity position supports investment and shareholder returns.

Total Liabilities
Balance Sheet
+12.1%
$1.3T$1.5T

Liabilities increased 12.1% — monitor debt-to-equity ratio and interest coverage.

Total Assets
Balance Sheet
+11.3%
$1.4T$1.6T

Asset base grew 11.3% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-11-03
PRIOR — 2025-08-04
ADDED
The Firm delivered ROE of 18.0% and ROTCE of 23.5% (see Selected Non-GAAP Financial Information herein).
The Firm s expense efficiency ratio was 67% for the third quarter and 69% for the year-to-date.
At September 30, 2025, the Firm s Standardized Common Equity Tier 1 capital ratio was 15.1%, and its Supplementary Leverage Ratio was 5.5%.
Institutional Securities reported net revenues of $8.5 billion reflecting strong performance in Equity on higher client activity and a rebound in Investment Banking .
Net revenues of $8.2 billion reflect higher Asset management and Transactional revenues and higher Net interest income.
+7 more — sign up free →
REMOVED
The Firm delivered ROE of 13.9% and ROTCE of 18.2% (see Selected Non-GAAP Financial Information herein).
The Firm s expense efficiency ratio was 71% for the second quarter and 70% for the year-to-date reflecting continued discipline in controllable spend, benefits from prior occupancy exits, and productivity gains through technology, partially offset by higher execution-related expenses.
At June 30, 2025, the Firm s Standardized Common Equity Tier 1 capital ratio was 15.0%.
Institutional Securities reported net revenues of $7.6 billion reflecting strong performance in our Markets business on higher client activity primarily in Equity.
Net revenues of $7.8 billion reflect higher Asset management revenues and higher Transactional revenues driven by increased client activity and the positive impact of investments associated with certain employee deferred cash-based compensation plans linked to investment performance ( DCP investments ) of $294 million.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →